共 50 条
- [4] Assessing the Efficacy of Rifaximin in Diarrhea-Predominant Irritable Syndrome (IBS-D): A Post hoc Analysis of 2 Phase 3, Randomized, Placebo-Controlled Trials [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S254 - S254
- [5] Safety and Tolerability of Rifaximin in the Treatment of Irritable Bowel Syndrome (IBS): A Pooled Analysis of 4 Randomized, Placebo-Controlled Trials [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S253 - S253
- [6] Rifaximin Improves Both Fecal Urgency and Stool Consistency in Adults With Irritable Bowel Syndrome With Diarrhea (IBS-D): A Composite Endpoint Analysis of Two Randomized, Phase 3 Trials [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S384 - S385
- [7] Efficacy of Rifaximin on Bowel Movement Urgency in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D): A Pooled Analysis of 3 Phase 3 Trials [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S253 - S254
- [8] Eluxadoline for the treatment of irritable bowel syndrome with diarrhea (IBS-D): results of two randomized, double-blind, placebo-controlled Phase 3 clinical trials [J]. PHARMACOTHERAPY, 2015, 35 (11): : E189 - E189
- [10] The Strong Association Between Bloating, Abdominal Pain, and Global Irritable Bowel Syndrome (IBS) Symptom Scores in IBS With Diarrhea (IBS-D): A Phase 3 Trial Pooled Correlation Analysis of Individual Symptoms [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S396 - S396